博晖创新：控股孙公司联合获得药物临床试验批准通知书

Core Viewpoint - The company announced that its subsidiary, Bohui Biopharmaceutical Co., Ltd., in collaboration with Beijing Baihui Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of a lyophilized type B Haemophilus influenzae conjugate vaccine [1] Group 1 - The clinical trial approval indicates progress in the development of the vaccine, which may enhance the company's product portfolio in the biopharmaceutical sector [1] - The collaboration with Beijing Baihui Biotechnology Co., Ltd. suggests a strategic partnership aimed at leveraging combined expertise for vaccine development [1]